PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Positive growth while AGEN shows decline. John Neff would investigate competitive advantages.
100.00%
Margin expansion while AGEN shows decline. John Neff would investigate competitive advantages.
7.04%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
-5.63%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
2.59%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth less than half of AGEN's 35.63%. David Dodd would verify if efficiency is sustainable.
-2.44%
EBITDA decline while AGEN shows 3.99% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Operating income decline while AGEN shows 5.91% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-3.66%
Pre-tax income decline while AGEN shows 4.33% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
-10.34%
Net income decline while AGEN shows 29.92% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-10.26%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.08%
Share count increase while AGEN reduces shares. John Neff would investigate differences.
0.08%
Diluted share increase while AGEN reduces shares. John Neff would investigate differences.